Abstract

Text-Size + –

• DNA sequencing has become less expensive and patients are requesting sequence information more often. The clinical utility of identifying genomic and/or somatic mutations remains uncertain in most cancers and especially in prostate cancer. However, clinical guidelines must offer guidance. The rapidly expanding knowledge base requires that guideline panels pay vigilant attention to the literature, advocate for clinical trials and correlative science, and provide frequent guideline updates.